Can laboratory tests at the time of admission guide us to the prognosis of patients with COVID-19?


Coronavirus, Mortality, Prognosis, Laboratory tests


Introduction: To enhance the COVID-19 patients’ care and to optimize utilizing medical resources during the pandemic, relevant biomarkers are needed for prediction of the disease’s progression, the current study was aimed to determine the factors that effect on mortality of COVID-19 patients who admitted in Baharloo hospital in Iran.

Methods: in the current retrospective study, 56 patients who were died because of COVID-19 infection were randomly selected from those who were admitted to Baharloo hospital. One patient who was diagnosed with COVID-19 and had recovered from it matched with each non-survived patient in the term of age. Laboratory tests of all these patients at the time of admission were recorded and compared. All analyses performed using spss version 22 by considering α:0.05 as a significant level.

Results: There was no statistical difference in the age and gender distribution between the two groups (p>0.05). The prevalence of diabetes among survived patients was 37.5% and among non-survived patients was 26.8% and there was no statistical difference between two groups about this comorbidity (p:0.22). Also, there was no statistical difference in the prevalence of hypertension and coronary heart diseases between two groups (p>0.05). Lymphocyte percentage, Blood oxygen level, and platelet (PLT) count was significantly higher in patients who had recovered (P<0.05).        

Conclusions: LDH level, Lymphocyte percentage, PLT count, and blood Oxygen saturation have associations with severe forms of COVID-19 infection and can be used as predictors to assess the patients who are suspected of infection with COVID-19 at the time of admission.


[1] Worldmeter. In.; 2020. available in:

[2] Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, Li P, Zhou Y, Lin Y, Duan Q: Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. Journal of Infection 2020.
[3] Lippi G, Plebani M, Henry BM: Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica Chimica Acta 2020.
[4] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet 2020.
[5] Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H: Factors Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Iranian journal of public health 2020, 49(7):1211-1221.
[6] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020, 55(3):105924.
[7] Liu Y, Eggo RM, Kucharski AJ: Secondary attack rate and superspreading events for SARS-CoV-2. Lancet 2020, 395(10227):e47.
[8] Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, Lee BY: The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. Health Aff (Millwood) 2020, 39(6):927-935.
[9] Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H: Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. Clinical Microbiology and Infection 2020.
[10] Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X: C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. Journal of Medical Virology 2020.
[11] Ruan Q, Yang K, Wang W, Jiang L, Song J: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine 2020:1-3.
[12] Wynants L, Van Calster B, Bonten MM, Collins GS, Debray TP, De Vos M, Haller MC, Heinze G, Moons KG, Riley RD: Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. bmj 2020, 369.
[13] Cvetanovska M, Milenkovik Z, Uroshevik VK, Demiri I, Cvetanovski V: Factors Associated with Lethal Outcome in Patients with Severe Form of Influenza. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2016, 37(2-3):63-72.
[14] Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, Long D, Yu L: Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets 2020, 31(4):490-496.
[15] Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, Luo M, Chen L, Zhao Y: Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection 2020.
[16] Min C-K, Cheon S, Ha N-Y, Sohn KM, Kim Y, Aigerim A, Shin HM, Choi J-Y, Inn K-S, Kim J-H: Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Scientific reports 2016, 6(1):1-12.
[17] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W: Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases 2020.
[18] Yang M, Ng MH, Li CK: Thrombocytopenia in patients with severe acute respiratory syndrome. Hematology 2005, 10(2):101-105.
[19] Lee IK, Liu JW, Wang L, Yang KD, Li CC, Eng HL: 2009 pandemic influenza A (H1N1): clinical and laboratory characteristics in pediatric and adult patients and in patients with pulmonary involvement. Influenza and other respiratory viruses 2012, 6(6):e152-e161.
[20] Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR: The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017, 544(7648):105-109.
[21] Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, Xiao S-Y: Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern Pathology 2020:1-8.
[22] Mo X, Wei F, Tong Y, Ding L, Zhu Q, Du S, Tan F, Zhu C, Wang Y, Yu Q: Lactic acid downregulates viral microRNA to promote Epstein-Barr Virus-immortalized B lymphoblastic cell adhesion and growth. Journal of virology 2018, 92(9):e00033-00018.
[23] Song YJ, Kim A, Kim GT, Yu HY, Lee ES, Park MJ, Kim YJ, Shim SM, Park TS: Inhibition of lactate dehydrogenase A suppresses inflammatory response in RAW 264.7 macrophages. Molecular medicine reports 2019, 19(1):629-637.
[24] Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E: Pneumocystis infection in humans: diagnosis and treatment. Expert review of anti-infective therapy 2010, 8(6):683-701.
[25] Huang L, Cattamanchi A, Davis JL, Boon Sd, Kovacs J, Meshnick S, Miller RF, Walzer PD, Worodria W, Masur H: HIV-associated Pneumocystis pneumonia. Proceedings of the American Thoracic Society 2011, 8(3):294-300.
[26] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z: Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology 2020.
[27] Agassandian M, Shurin GV, Ma Y, Shurin MR: C-reactive protein and lung diseases. The international journal of biochemistry & cell biology 2014, 53:77-88.
[28] Heuertz RM, Ahmed N, Webster RO: Peptides derived from C-reactive protein inhibit neutrophil alveolitis. The Journal of Immunology 1996, 156(9):3412-3417.
[29] Ling W: C-reactive protein levels in the early stage of COVID-19. Medecine et maladies infectieuses 2020.